The article presents a study which compares rates of febrile neutropenia (FN), overall survival (OS), hormone adherence rates (HA) and disease-free survival (DFS) in women under age 50 and women over 50 years old undergoing 5-flurouracil +epirubicin+cyclophosphamide (FEC-T). Topics discussed include choice of endpoints to assess nausea and vomiting, acute pain syndrome with taxanes, and carcinoid heart disease.